Novo Nordisk's Obesity Drug Candidate Amycretin Delivers Up to 24% Weight Reduction

05:55 AM EDT, 06/22/2025 (MT Newswires) -- Novo Nordisk's (NOVO-B.CO) experimental drug, amycretin, resulted in the loss of up to 24.3% weight in overweight or obese patients, according to the full results of two early-stage clinical trials. The Danish drugmaker's subcutaneous and oral amycretin data suggested that a longer treatment duration may potentially facilitate additional weight loss, according to a June 20 release. The drug's safety profile was consistent with other GLP-1 and amylin receptor agonists, Novo said as it prepares for phase 3 amycretin trials.